Skip to content
Open access

Humoral and cellular responses to SARS‐CoV‐2 variants after ancestral COVID‐19 vaccines in people with HIV and lung transplant recipients

Aug 2026 · Clinical & Translational Immunology · Vol 15 · 0 citations · 72 references
Medicine

TL;DR

Immunocompromised groups had reduced but detectable SARS‐CoV‐2‐specific memory T cells and a reduced functional memory T‐cell response in LTx, demonstrating the utility of COVID‐19 vaccination despite poorer serological responses.

Abstract

Abstract Objectives Immunocompromised hosts have reduced immune responses to COVID‐19 vaccination, and more severe disease. Antibody responses correlate with protection but markers of immunity vary across a spectrum of immunocompromise. We compared serologic and cellular responses following Ancestral COVID‐19 vaccines in healthy controls (HC), people with HIV (PWH) and lung transplant (LTx) recipients. Methods Anti‐spike receptor binding domain (RBD) IgG, neutralising antibodies (nAb) and T‐cell responses were assessed one‐month post‐dose 2 and dose 3 of Ancestral COVID‐19 vaccination in HC, PWH and LTx. NAb responses to Ancestral, Delta and Omicron BA.2 and BA.5 variants were assessed. Results Twenty‐nine HC, 21 PWH and 12 LTx recipients were included. PWH demonstrated lower anti‐RBD‐IgG responses (median post‐dose 3: 80.3 μg mL−1 vs 43.3 μg mL−1, P = 0.03) to mRNA COVID‐19 vaccination than HC, while LTx recipients displayed diminished responses following any vaccine (15.3 μg mL−1 vs 74.0 μg mL−1, P = 0.01). Dose 3 increased anti‐RBD‐IgG concentrations and nAb responses in HC and PWH, though Omicron variant neutralisation was attenuated. LTx recipients mounted limited nAb responses. PWH and HC had no difference in nAb responses for Ancestral (median 1738 vs 486.2, P > 0.99) or BA.5 variants (median 34.0 vs 67.9, P > 0.99). Compared with HC, PWH and LTx demonstrated reduced frequencies of SARS‐CoV‐2‐specific memory T cells and a reduced functional memory T‐cell response in LTx. Conclusion Although Dose 3 was beneficial, LTx recipients demonstrated lower serological responses than HC, while reductions were modest in PWH. Immunocompromised groups had reduced but detectable SARS‐CoV‐2‐specific T‐cell responses, demonstrating the utility of COVID‐19 vaccination despite poorer serological responses.

Read PDF

Similar papers

Review Open access Sep 2026

Measurement of binding antibodies to SARS-CoV-2 variants elicited by natural infection and COVID-19 vaccines in a sub-Saharan African population

These findings provide rare data on variant-specific vaccine-elicited antibody binding responses in West and Central African populations with distinct demographic, epidemiologic, and immunologic background.

E. Lusamaki, Ana M. Ortega-Villa, Daouda Camara et al. · 0 citations
Open access Sep 2026

Age-specific humoral immune response to SARS-CoV-2: A comparative analysis of antibody levels in children and adults after vaccination with primary series or infection

COVID-19 immune responses differ between children and adults, with adolescents exhibiting stronger immune response to vaccination than children younger than 12, however vaccine dosage may play a role in this observed difference.

Brooke A. Hawkes, J. Hollister, Cynthia Porter et al. · 0 citations
Open access Sep 2026

Memory B cell response to SARS-CoV-2 vaccination in people with heart and lung transplantation: Identification of associated clinical factors

Summary Solid organ transplant recipients (SOT) have shown impaired immune responses to infection and vaccination. Here, serological data collected in heart and lung transplant recipients after vaccination against SARS-CoV-2 were analyzed using dimensionality reduction, clustering algorithms and statistical methods to...

Chiara Coppola, Simone Costagli, G. Montesi et al. · 0 citations
Review Open access Sep 2026

Cross‐Neutralization Responses and Persistent Symptoms After SARS‐CoV‐2 Breakthrough Infections

The cross‐NAb landscape in a real‐world Chinese population after a 3‐year zero‐COVID strategy is defined, showing modest broadening of humoral immunity following multiple exposures, but antigenic divergence of emerging Omicron sub‐variants continues to limit cross‐protection, supporting the need for variant‐adapted vac...

Ting Yang, Rong Zhang, Shi-Jie Qin et al. · 0 citations
Sep 2026

CD4 Count and CD4/CD8 Ratio Impact Antibody Responses to COVID-19 mRNA Booster Vaccination in People with HIV on Suppressive ART.

CD4+ T cell count influences antibody persistence, while the CD4/CD8 ratio affects initial antibody magnitude and Tfh cell frequencies, highlighting complementary roles in shaping vaccine responses in PLWH.

Roser Navarro-Soler, M. J. Heise, T. Dalhuisen et al. · 0 citations
Open access Oct 2026

Systemic T-Cell Activation Landscapes Elicited Following Intramuscular and Intranasal Immunization with the Active NDV-Vectored Anti-COVID-19 Vaccine “Patria” in Humans

COVID-19 vaccines remain essential for pandemic control, but antibody responses wane, and viral variants emerge. Affordable platforms enabling local manufacturing are important for equitable vaccine access in low- and middle-income countries (LMICs). The locally developed and manufactured NDV-vectored AVX/COVID-12 “Pat...

Claudia Carranza, Alejandro Torres-Flores, Dámaris P. Romero-Rodríguez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.